Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15365145.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents, Alkylating
- Central Nervous System Neoplasms
- Dacarbazine
- Immunotherapy
- Lymphoma, B-Cell
- Salvage Therapy